Thrombopoietin agonist(The Scripps Research Institute)

Swedish Orphan Biovitrum (Sobi) has said it will acquire CTI BioPharma for approximately $1.7bn, marking a notable expansion to the Swedish drugmaker's rare haematology pipeline. The deal will grant Sobi access to the US biopharma’s recently-approved Vonjo (pacritinib), a novel oral kinase inhibitor for patients with myelofibrosis and severe thrombocytopenia. The drug was granted accelerated approval by the US Food and Drug Administration (FDA) in February last year to treat adults with intermediate or high-risk primary or secondary myelofibrosis with low platelet counts. This was based on positive results from a phase 3 trial of Vonjo in patients with myelofibrosis. Results showed that 29% of patients receiving Vonjo had a reduction in spleen volume of at least 35% compared to 3% of patients receiving best available therapy. Sobi said Vonjo will be ‘highly complementary’ to Doptelet (avatrombopag), its oral thrombopoietin receptor agonist which also addresses rare haematological platelet disorders. Guido Oelkers, Sobi’s president and chief executive officer, said: “CTI represents a perfect fit for Sobi’s haematology franchise today, adding a powerful and highly differentiated new product that will make a significant difference for patients.” “The combination of the talented team at CTI, together with Sobi’s broad US and global haematology capabilities, will help get this much needed new therapy to patients faster and more effectively,” Oelkers added. Under the terms of the agreement, Sobi will make a tender offer for $9.10 per CTI share, a premium of 89% the company's closing price of $4.82 earlier this week. The transaction is expected to close in the third quarter of this year. Adam Craig, president, chief executive officer and interim chief medical officer of CTI BioPharma, said: "We are delighted to announce this transaction, which delivers a compelling all-cash premium to our shareholders, while positioning CTI to unlock the full potential of Vonjo in treating myeloproliferative disease." The deal comes a few months after Sobi and partner Sanofi’s once-weekly haemophilia A treatment, Altuviiio, was approved by the FDA for the prevention and on-demand treatment to control bleeding episodes, as well as for surgery management for adults and children with the disease.

DUBLIN--( BUSINESS WIRE )--The "Immune Thrombocytopenia (ITP) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape" report has been added to ResearchAndMarkets.com's offering. This reports provides a data-driven overview of the current and future competitive landscape in ITP therapeutics. Key Highlights There will be more than 1.6 million diagnosed prevalent cases of ITP in 2023 across 16 pharmaceutical markets. There are four leading marketed innovator drugs for the treatment of ITP, majority of marketed products are thrombopoietin receptor agonist. R&D activity in ITP is significant, with nine products in Phase III development. Novartis has sponsored the highest number of clinical trials (nine) in ITP over the past 10 years. In deals involving ITP assets, licensing agreements are the most common type of deal globally. New innovator drugs are expected to enter the ITP market only after the next two years. Scope The publisher's Immune Thrombocytopenia (ITP) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace. Components of the report include: Disease Landscape Disease Overview Epidemiology Overview Treatment Overview Marketed Products Assessment Breakdown by Mechanism of Action, Molecule Type, Route of Administration Product Profiles with Sales Forecast Pricing and Reimbursement Assessment Retail or Manufacturer Price of Products Time to Pricing and Time to Reimbursement Pipeline Assessment Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration Product Profiles with Sales Forecast Late-to-mid-stage Pipeline Drugs Phase Transition Success Rate and Likelihood of Approval Clinical Trials Assessment Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status Enrolment Analytics, Site Analytics, Feasibility Analysis Deals Landscape Mergers, Acquisitions, and Strategic Alliances by Region Overview of Recent Deals Commercial Assessment Key Market Players Future Market Catalysts Reasons to Buy Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Develop business strategies by understanding the trends shaping and driving the ITP market. Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global ITP market in the future. Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships. Key Topics Covered: 1 Preface 1.1 Contents 1.2 Report Scope 1.3 List of Tables and Figures 1.4 Abbreviations 2 Key Findings 3 Disease Landscape 3.1 Disease Overview 3.2 Epidemiology Overview 3.3 Treatment Overview 4 Marketed Drugs Assessment 4.1 Leading Marketed Drugs 4.2 Overview by Mechanism of Action 4.3 Overview by Route of Administration 4.4 Marketed Drugs Profiles and Sales Forecasts 5 Pricing and Reimbursement Assessment 5.1 Manufacturer Price 5.2 Time to Pricing and Reimbursement 6 Pipeline Drugs Assessment 6.1 Phase III Pipeline Drugs 6.2 Overview by Development Stage 6.3 Overview by Molecule Type 6.4 Overview by Mechanism of Action 6.5 Overview by Route of Administration 6.6 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA) 6.7 Therapy Area and Indication-specific PTSR and LoA 7 Clinical Trials Assessment 7.1 Historical Overview 7.2 Overview by Phase 7.3 Overview by Status 7.4 Overview by Phase for Ongoing and Planned Trials 7.5 Trials with Virtual Components 7.6 Geographic Overview 7.7 Single-Country and Multinational Trials by Region 7.8 Top 20 Sponsors with Breakdown by Phase 7.9 Top 20 Sponsors with Breakdown by Status 7.10 Overview by Endpoint Status 7.11 Overview by Race and Ethnicity 7.12 Enrollment Data 7.13 Top 20 countries for Trial Sites 7.14 Top 20 Sites Globally 7.15 Feasibility Analysis - Geographic Overview 7.16 Feasibility Analysis - Benchmark Models 8 Deals Landscape 8.1 Mergers, Acquisitions, and Strategic Alliances by Region 8.2 Recent Mergers, Acquisitions, and Strategic Alliances 9 Commercial Assessment 9.1 Key Market Players 10 Future Market Catalysts 11 Appendix For more information about this report visit https://www.researchandmarkets.com/r/rmu1tn Source: GlobalData About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.